SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and Viking Therapeutics, Inc.

SG&A Efficiency: A Tale of Two Biotechs

In the competitive world of biotechnology, managing operational expenses is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of ADMA Biologics, Inc. and Viking Therapeutics, Inc. over a decade, from 2014 to 2023.

ADMA Biologics, Inc.

ADMA Biologics has seen a significant increase in SG&A expenses, growing by over 1,100% from 2014 to 2023. This rise reflects the company's aggressive expansion and investment in operational capabilities. By 2023, their SG&A expenses reached nearly $59 million, indicating a robust growth strategy.

Viking Therapeutics, Inc.

In contrast, Viking Therapeutics experienced a more moderate increase of approximately 2,900% in the same period, with expenses peaking at around $37 million in 2023. This suggests a more conservative approach to scaling operations.

Conclusion

Understanding these trends provides valuable insights into each company's strategic priorities and operational efficiency.